Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX https://t.co/7lFqrfL3fF
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels. https://t.co/meig18rSEX
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics https://t.co/ToK3AmcAoX
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA
02 Aug 2017 Social FDA Arthritis Advisory Panel votes against (12-2) approval of Sirukumab (IL6 inhib) for use in RA. FDA decision pending.
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS https://t.co/c1PW8aglhU
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co…
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx http://t.co/wrucZOW9HC
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij
23 Aug 2016 Social Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
07 Dec 2017 Social Prospective study of 133 IBD pts (64% CD, 36% UC) switched from Remicade to biosimilar Inflectra. After 12 mos. no differences in drug levels, disease activity between innovator and biosimilar. https://t.co/QEH3lUaXD4
06 Aug 2018 Social Psoriasis biologic pipeline continues to grow. In development are IL-23 inhibitors (risankizumab, mirikizumab) & the IL-17 A/F inhbitor (bimekizumab). Tildrakizumab and certolizumab were approved for Psoriasis earlier in 2018. https://t.co/QFbdtO1Lua
27 Aug 2015 Social Review of immunogenicity and biologic agents. (does this make you think you should monitor Anti-Drug Abs?) http://t.co/qfuGrbD83i
05 Nov 2017 Social RT @WIRheum: Great debate: patient and provider preferences around biosimilar use from @RheumNow survey #ACR17 https://t.co/MgBXZ9gyeV
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/iYAzWwsyi2
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA) https://t.co/xmAuMJN4Gd
03 Oct 2018 Social RT @RheumNow: Often Not discussed but do you combine Otezla with a biologic (TNFi or IL-17 inhibitor) in your difficult PsA patients? Rheum…
17 Jun 2019 Social Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb